FDA Looks To Placate Amarin, Duck Free Speech Decision

Law360, New York (June 8, 2015, 9:11 PM EDT) -- The U.S. Food and Drug Administration in a letter released Monday told Amarin Pharma Inc. it can make numerous off-label statements about fish oil medicine Vascepa, a move likely designed to short-circuit the company's potentially precedent-setting challenge to restrictions on free speech, experts say.

The letter was described by the FDA as an attempt to narrow the scope of a closely watched constitutional challenge that Amarin launched last month, with regulators saying they don’t object to most of what the Irish drugmaker wants to tell doctors...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Amarin Pharma, Inc. et al v. United States Food & Drug Administration et al


Case Number

1:15-cv-03588

Court

New York Southern

Nature of Suit

Other Statutory Actions

Judge

Paul A. Engelmayer

Date Filed

May 7, 2015

Law Firms

Companies

Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.